{
    "name": "umbralisib",
    "comment": "Discontinued",
    "other_names": [
        "Ukoniq"
    ],
    "classes": [
        "Antineoplastics",
        "PI3K Inhibitors",
        "Antineoplastics",
        "CDK Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/ukoniq-umbralisib-4000153",
    "pregnancy": {
        "common": [
            "May cause fetal harm when administered to pregnant females",
            "Data are not available on use in pregnant females",
            "Verify pregnancy status in females of reproductive potential before initiation"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Administration to pregnant mice during organogenesis resulted in adverse developmental outcomes (eg, alterations to growth, embryofetal mortality, structural abnormalities) at maternal exposures (AUC) comparable to 800-mg dose"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 1 month after last dose",
                    "Males with female partners of reproductive potential: Use effective contraception during treatment and for 1 month after last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on findings from mice and dogs, male fertility may be impaired",
                    "Trend for reversibility noted in dogs 30 days after last dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data available on presence in milk, effects on breastfed children, or milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Serious neutropenia reported; monitor and consider appropriate supportive care",
                "Serious diarrhea or noninfectious colitis occurred; monitor for development of diarrhea or colitis and provide supportive care (ie, antidiarrheals, enteric-acting steroids) as appropriate ",
                "Serious hepatotoxicity occurred; median time to onset for grade ≥3 elevated AST/ALT monitor hepatic function ",
                "Contains FD&C yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma); incidence of sensitivity frequently seen in patients who also have aspirin hypersensitivity",
                "Can cause fetal harm when administered to pregnant females"
            ],
            "specific": [
                {
                    "type": "Infections",
                    "description": [
                        "Serious, including fatal, infections occurred",
                        "Monitor for fever, CMV infection, and any new or worsening signs and symptoms of infection",
                        "Evaluate promptly and treat as needed",
                        "Provide prophylaxis for ",
                        "Pneumocystis jirovecii pneumonia",
                        " (PJP) and consider prophylactic antivirals for CMV prevention during treatment"
                    ]
                },
                {
                    "type": "Severe cutaneous reactions",
                    "description": [
                        "Severe cutaneous reactions, including a fatal case of exfoliative dermatitis",
                        "Monitor for new or worsening cutaneous reactions",
                        "Review all concomitant medications and discontinue any potentially contributing medications",
                        "Provide supportive care as appropriate"
                    ]
                },
                {
                    "type": "Increased risk of death",
                    "description": [
                        "February 2, 2022:",
                        " FDA ",
                        " is investigating possible increased risk of death with umbralisib ",
                        "FDA determined that initial findings from a clinical trial showed or reported a possible increased risk of death in treated patients taking the medicine",
                        "FDA is re-evaluating this risk against the benefits of umbralisib for its approved uses; results from UNITY trial will continue to be evaluated and a future public meeting will discuss findings and explore continued marketing of umbralisib",
                        "Enrollment of new patients in other ongoing umbralisib clinical trials has been suspended while findings are being reviewed ",
                        "Review patients’ progress on umbralisib and discuss the risks and benefits of continuing treatment in the context of other available treatments"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Substrate of CYP1A2, CYP2C9, and CYP3A4",
                        "Inhibits CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-gp; induces CYP3A4",
                        "Coadministration with strong CYP3A4 or CYP2C9 inhibitors and inducers: Not studied",
                        "Coadministration with sensitive substrates of CYP3A4, CYP2C8, CYP2C9 and CYP2C19, or P-gp substrates: Not fully characterized"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Creatinine increased",
            "percent": "79"
        },
        {
            "name": "Diarrhea",
            "percent": "58"
        },
        {
            "name": "Fatigue",
            "percent": "41"
        },
        {
            "name": "Nausea",
            "percent": "38"
        },
        {
            "name": "Neutrophils decreased",
            "percent": "33"
        },
        {
            "name": "ALT increased",
            "percent": "33"
        },
        {
            "name": "AST increased",
            "percent": "32"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "27"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "27"
        },
        {
            "name": "Platelets decreased",
            "percent": "26"
        },
        {
            "name": "Potassium decreased",
            "percent": "21"
        },
        {
            "name": "Vomiting",
            "percent": "21"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "21"
        },
        {
            "name": "Abdominal pain",
            "percent": "19"
        },
        {
            "name": "Decreased appetite",
            "percent": "19"
        },
        {
            "name": "Rash",
            "percent": "18"
        },
        {
            "name": "Edema",
            "percent": "14"
        },
        {
            "name": "Insomnia",
            "percent": "14"
        },
        {
            "name": "Neutrophil decreased",
            "percent": "16"
        },
        {
            "name": "Pyrexia",
            "percent": "10"
        },
        {
            "name": "Urinary tract infection",
            "percent": "9"
        },
        {
            "name": "Dyspnea",
            "percent": "7"
        },
        {
            "name": "Pneumonia",
            "percent": "6"
        },
        {
            "name": "Sepsis",
            "percent": "3"
        },
        {
            "name": "Colitis",
            "percent": "2"
        },
        {
            "name": "Diarrhea",
            "percent": "10"
        },
        {
            "name": "ALT increased",
            "percent": "8"
        },
        {
            "name": "AST increased",
            "percent": "7"
        },
        {
            "name": "Platelets decreased",
            "percent": "4"
        },
        {
            "name": "Potassium decreased",
            "percent": "4"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "3"
        },
        {
            "name": "Rash",
            "percent": "3"
        },
        {
            "name": "Fatigue",
            "percent": "3"
        },
        {
            "name": "Abdominal pain",
            "percent": "3"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "2"
        },
        {
            "name": "Decreased appetite",
            "percent": "2"
        },
        {
            "name": "Pneumonitis",
            "percent": null
        },
        {
            "name": "Exfoliative dermatitis",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        }
    ]
}